Delivery Order 75D30124D20079-75D30125F00003
Award Date
1/16/25
Potential Completion Date
5/15/25
Potential Value
$450K
Federal Agency
CDC Pittsburgh
Awardee
Ginkgo Bioworks, Inc.
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Time and Materials
Place of Performance
Boston, MA 02210, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
4
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $50,216,772.13 Firm Fixed Price Delivery Order contract was awarded to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract is for test surge and data sharing services under a larger Indefinite Delivery/Indefinite Quantity (IDIQ) vehicle held with the Centers for Disease Control and Prevention (CDC). The IDIQ has a total ceiling value of $118 million and an ultimate completion date of September 5, 2029. Ginkgo Bioworks has previously provided...
This federal contract award is for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the Centers for Disease Control and Prevention (CDC) for "Test Surge and Data Sharing" services. The $118 million IDIQ was awarded to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts, on September 27, 2024. The contract has an ultimate completion date of September 5, 2029. This IDIQ is not designated as a set-aside contract. The IDIQ contract leverages...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $85,741,227.24 Firm Fixed Price Definitive Contract to Ginkgo Bioworks, Inc., a biotechnology company in Boston, Massachusetts, for a Traveler-Based Genomic Surveillance Program. The contract has an ultimate completion date of March 21, 2028 and was not set aside for a specific business category. This contract appears to build on Ginkgo Bioworks' previous work with the CDC on COVID-19 genomic testing and surveillance at major...
This is a $1,205,149.24 Firm Fixed Price contract awarded by the Centers for Disease Control and Prevention (CDC) to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract, titled "TRAVELER-BASED GENOMIC SURVEILLANCE," is for the provision of biotechnology services to support the CDC's public health monitoring and emergency response initiatives. The contract has an ultimate completion date of September 19, 2024 and was awarded on August 26, 2024....
The Centers for Disease Control and Prevention (CDC) awarded a $76,575,638.04 firm-fixed-price contract to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, to conduct genomic testing and surveillance of SARS-CoV-2 at five major U.S. international airports. The contract, which runs through March 21, 2025, requires Ginkgo Bioworks to collect a minimum of 483,000 biological samples per year from international travelers and perform on-site reverse transcription polymerase chain...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a firm-fixed-price delivery order to Aegis Sciences Corporation, a for-profit organization, to provide Test Surge and Data Sharing services. This order was placed under a multiple-award indefinite-delivery, indefinite-quantity (IDIQ) contract with a total ceiling value of $2,427,648.50 and a period of performance through September 26, 2029. Aegis, operating out of its laboratory in Nashville, Tennessee, will perform COVID-19...
The National Institutes of Health's National Heart, Lung and Blood Institute awarded Ginkgo Bioworks, Inc. a $6.57 million firm fixed price definitive contract to support the Rapid Acceleration of Diagnostics-Advanced Technology Platforms program. The goal of this program is to increase SARS-CoV-2 testing capacity and throughput by identifying existing testing platforms that can be used for COVID-19 diagnostics. Work will be performed by Ginkgo Bioworks in Boston, Massachusetts over a one year...
The Centers for Disease Control and Prevention (CDC) awarded a $39.9 million firm fixed price definitive contract to Aegis Sciences Corporation for COVID-19 genome sequencing services. As the prime contractor, Aegis Sciences Corporation will perform the sequencing work out of its Nashville, Tennessee laboratory. The one year contract is intended to support the CDC's ongoing efforts to track genetic variations of the SARS-CoV-2 virus through genomic surveillance. No subcontractors or set aside...
This federal contract award to Eagle Global Scientific LLC is a $2,235,934.74 delivery order issued by the Centers for Disease Control and Prevention (CDC), a civilian agency within the Department of Health and Human Services (HHS). The contract is for professional and technical services to support the CDC's disease monitoring and prevention programs, particularly related to respiratory illnesses, healthcare-associated infections, and the COVID-19 response. The contract is a time and materials...
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) awarded a Firm Fixed Price purchase order to Illumina, Inc., a manufacturer of sequencing and genomic analysis solutions, for the provision of lab supplies. The $16,168.00 contract has an April 29, 2024 completion date and was awarded on August 22, 2019. The lab supplies are to be delivered to the CDC's location in Atlanta, GA. Illumina is a for-profit organization and manufacturer that has previously...